Holen Sie sich die Stockscreener-App
19.45
1.97%
-0.39
Handel nachbörslich:
19.45
Schrodinger Inc Aktie (SDGR) Neueste Nachrichten
Schrödinger Drops CDC7 Inhibitor SGR-2921 After Two Patient Deaths - insights.citeline.com
This AZZ Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga
Schrödinger stops development of blood cancer therapy after two patient deaths - Reuters
Schrödinger Inc. Shows Early Signs of Technical StrengthInflation Watch & Short-Term High Return Ideas - beatles.ru
Schrodinger initiated with an Overweight at Barclays - TipRanks
Schrödinger Inc. Reaches Critical Trendline SupportTake Profit & Reliable Breakout Stock Forecasts - newsyoung.net
Schrodinger discontinues SGR-2921 clinical development program - TipRanks
Schrödinger Stock Plummets After Halting Key Leukemia Drug Program - MSN
Schrodinger drops 16% as it abandons leukemia candidate - MSN
Schrodinger stock plunges after discontinuing key leukemia drug By Investing.com - Investing.com India
Schrodinger stock plunges after discontinuing key leukemia drug - Investing.com UK
Schrödinger stock tumbles after discontinuing cancer drug program By Investing.com - Investing.com Nigeria
Schrödinger stock tumbles after discontinuing cancer drug program - Investing.com
Schrodinger falls after ending blood cancer therapy development on patient deaths - TradingView
Schrodinger Discontinues SGR-2921 Program Following Deaths of Two AML Patients - MarketScreener
Schrodinger, Inc. Announces Discontinuation of Clinical Development Program for SGR-2921 - MarketScreener
Schrödinger Discontinues Clinical Program After Two Patient Deaths By Stocktwits - Investing.com India
Schrödinger Discontinues Clinical Program After Two Patient Deaths - Stocktwits
Barclays Initiates Schrodinger at Overweight With $25 Price Target - MarketScreener
Schrödinger discontinues leukemia drug after patient deaths - Investing.com
Schrödinger Announces Discontinuation of SGR-2921 Program - Yahoo Finance
Barclays initiates Schrodinger stock with Overweight rating on upcoming catalysts - Investing.com Nigeria
How Investors May Respond To Schrödinger (SDGR) Affirming 2025 Guidance Amid Revenue Growth and Narrowing Losses - simplywall.st
Schrodinger, Inc. Earnings Call: Growth Amid Challenges - TipRanks
What risks could impact Schrödinger Inc. stock performanceMarket Opportunity Tracker for Swing Traders - Newser
Risk adjusted return profile for Schrödinger Inc. analyzedSecure Asset Flow and Trend Pattern Analysis - Newser
Using AI based signals to follow Schrödinger Inc.Strategy Playbook for Risk Controlled Trades - Newser
How to track smart money flows in Schrödinger Inc.Smart Stock Forecast Using AI Algorithms - Newser
Analyzing recovery setups for Schrödinger Inc. investorsStable Swing Setup with Safety Analysis - Newser
Schrödinger maintains 10–15% software revenue growth guidance while advancing SGR-1505 clinical program - MSN
A Quick Look at Today's Ratings for Schrodinger(SDGR.US), With a Forecast Between $30 to $35 - 富途牛牛
Zurcher Kantonalbank Zurich Cantonalbank Sells 538 Shares of Schrodinger, Inc. (NASDAQ:SDGR) - Defense World
Schrödinger, Inc. Reports Strong Q2 2025 Results - The Globe and Mail
Institutional scanner results for Schrödinger Inc.Free Wealth Building Stock Market Ideas - Newser
Citi Affirms Buy Rating on Schrödinger (SDGR) amid Expanded Collaboration with Ajax Therapeutics - MSN
Craig-Hallum Maintains Schrodinger(SDGR.US) With Buy Rating, Announces Target Price $30 - 富途牛牛
Schrodinger 2025 Q2 Earnings Narrowed Losses with 20.3% EPS Improvement - AInvest
Earnings call transcript: Schrodinger beats Q2 2025 forecasts, stock dips By Investing.com - Investing.com Canada
Earnings call transcript: Schrodinger beats Q2 2025 forecasts, stock dips - Investing.com India
Decoding Schrodinger Inc (SDGR): A Strategic SWOT Insight - GuruFocus
Schrödinger's Dual-Track Strategy: Software Growth and Clinical Pipeline Progress - AInvest
What’s next for Schrödinger Inc. stock priceShort-Term AI-Based Stock Price Forecast - Newser
Schrödinger's Q2 2025: Unpacking Contradictions in Customer Engagement, Toxicology Feedback, and Revenue Confidence - AInvest
Transcript : Schrödinger, Inc., Q2 2025 Earnings Call, Aug 06, 2025 - MarketScreener
Schrödinger, Inc. 2025 Q2ResultsEarnings Call Presentation (NASDAQ:SDGR) - Seeking Alpha
Schrödinger (SDGR) Q2 2025 Earnings Transcript - Mitrade
Schrodinger, Inc. (SDGR) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
Schrodinger Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Schrödinger Q2 2025 slides: Revenue grows 16% as company maintains full-year guidance - Investing.com Nigeria
Schrödinger Q2 2025 slides: Revenue grows 16% as company maintains full-year guidance By Investing.com - Investing.com South Africa
Schrodinger earnings beat by $0.15, revenue topped estimates - Investing.com India
Schrodinger Inc (SDGR) Q2 2025 Earnings: EPS of -$0.59 Beats Estimate, Revenue Surpasses Forecast at $54.8 Million - GuruFocus
Science and tech firm Schrodinger Q2 revenue beats expectations - MarketScreener
Schrödinger Reports Second Quarter 2025 Financial Results - Yahoo Finance
Why Opendoor Technologies Stock Was Tumbling Today - The Globe and Mail
1.47%
1.35%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):